KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Debt to Equity: 2009-2024

Historic Debt to Equity for Biomarin Pharmaceutical (BMRN) over the last 10 years, with Jun 2024 value amounting to $0.09.

  • Biomarin Pharmaceutical's Debt to Equity was N/A to $0.09 in Q2 2024 from the same period last year, while for Jun 2024 it was $0.09, marking a year-over-year change of. This contributed to the annual value of $0.10 for FY2023, which is 2783.06% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Debt to Equity stood at $0.09 for Q2 2024, which was down 3.93% from $0.10 recorded in Q1 2024.
  • Biomarin Pharmaceutical's 5-year Debt to Equity high stood at $0.11 for Q2 2020, and its period low was $0.00 during Q4 2022.
  • For the 3-year period, Biomarin Pharmaceutical's Debt to Equity averaged around $0.05, with its median value being $0.05 (2022).
  • Per our database at Business Quant, Biomarin Pharmaceutical's Debt to Equity skyrocketed by 3,310.96% in 2020 and then crashed by 93.45% in 2021.
  • Biomarin Pharmaceutical's Debt to Equity (Quarterly) stood at $0.09 in 2020, then slumped by 87.76% to $0.01 in 2021, then tumbled by 69.40% to $0.00 in 2022, then soared by 2,783.06% to $0.10 in 2023, then reached $0.09 in 2024.
  • Its last three reported values are $0.09 in Q2 2024, $0.10 for Q1 2024, and $0.10 during Q4 2023.